Committed to trials of Low Dose Naltrexone as a treatment for autoimmune diseases

Text Resize

-A +A

LDN and Fibromyalgia

Study shows Low-Dose Naltrexone eases Fibromyalgia pain

For sufferers of fibromyalgia, their condition is not just painful but made doubly worse by the lack of proper treatment for it and the uncertainty over the condition in the medical community. Now there is good news. A recent study indicates that Low-Dose Naltrexone does indeed ease the pain of fibromyalgia. 

2014 Feb 15.


The study was reported at the 28th annual meeting of the American Academy of Pain Medicine at Palm Springs, California on 27 February, 2012. For those who are confused about their condition and wondering whether they needed to cash in their Aviva Life and head off around the world to find a cure, the news suggests that a much simpler and cheaper solution is at hand. 

The study, rated among the top six at the meeting, was headed by Dr Jarred Younger, PhD, of the Stanford University School of Medicine, Palo Alto, California. Dr Younger's team had previously conducted a pilot study which indicated that Low-Dose Naltrexone worked in this way. He mentioned that further studies were necessary to explore dosages and other drugs. 

Dr Younger believes that the drug supresses the function of the microglia, rather than working as an opioid antagonist. Some of the great advantages of Low-Dose Naltrexone according to the study are that it appears to have small amount of side effects and the body has an easy tolerance of it, it is also relatively inexpensive and easy to get hold of. 

The study was completed by 27 women with an average age of 43, who were asked to record their daily pain and symptoms over two weeks of baseline monitoring, 12 of Low-Dose Naltrexone (4.5 mg a day), four weeks of placebo and four weeks of follow up. This close monitoring allowed the study to see with a great deal of detail exactly what happens when people start taking the medication. 

The most important result showed that pain reduction compared to those taking the placebo was statistically significant. There were adverse affects, but these were not judged as too serious: vivid dreams and headaches. These look especially good when compared to other fibromyalgia treatments such as milnacipran, duloxetine, and pregabalin. 

This is all great news for sufferers of fibromyalgia, we look forward to hearing of more research from Dr Younger's team.